Because, under the current the SEC 15-12g filling the company is officially dark and not allowed to promote the stock.
On the other hand, We are allowed to find public traces of activity, new and old and act on them.
The custodian court records last year were the first clues someone was wanting to take over the $MILV shell, legally and properly by court order, by a judge, which they did.
The Custodian snail mailed a shareholder meeting notice to known MILV shareholders, which was our next major clue. It was a huge clue!!!!
Beyond that, Company name was updated by the custodian at the Nevada SOS, to NDT Pharmaceuticals Inc. Confirming it is a Biotech.
James Hovis, the managing shareholder of CCA, LLC, the company named recently by the custodian in the shareholder snail mail letter, listed his name on the OTCmarkets $MILV page, and his resume, and address and phone number as the new CEO of $MILV.
That means Hovis, will signing the SEC Fillings when they arrive from the lawyers and auditors. It will 1-2 years of 10-K financials and what some super 8-K(?) listing the UPennMed Contract, and financials for CCA, LLC for the last years.
It means when the Custodian does his last task and resigns and names James Hovis as the CEO and as a director, and names the other officers and directors, the light switches will turned on.
I can see several things causing the delay. Auditors have been caught flat footed by travel restrictions and lock downs over the COVID19 crisis, and the SEC has approved 45 day delays in the normal 10-K due dates for auditors.
MILV is likely at the bottom of the food chain on the customer lists right now for the 10-K work to be completed.
CCA, LLC had to name MILV NDT Pharmaceuticals Inc and buy a website, and lock down the website and company name change, before moving the CCA, LLC JV contract, on paper from CCA, LLC to NDT Pharmaceuticals Inc. They need the new name and web site first.
Then they needed to declare Hovis the CEO of MILV, which they did at OTCMarkets most recently and at the same time declared the companies new address and phone and CEO's name.
So now he can legally sign for CCA, LLC and MILV (or I guess the custodian can still sign for MILV just as long as he is still listed at the Nevada SOS, and has not signed out and declared Hovis the new CEO, and that may be why the custodian is still listed).
So financials by auditors may be delayed by COVID19 which the SEC has given all companies an extra 45 days past the normal late date. Law firm needs to be named and read the S-1 filling and financials.
The JV legal document deal with UPennMed needs to be redone and assigned by both parties from CCA, LLC to MILV.
They may be finalizing a deal (lawyers on both sides) with Michael Fountain on a job and assignment of his newest patent for the 1-20 nm liposomes.
AND!!!!! Fountain's patent law firm is according to public records at the USPTO Patent Trademark Office burning the midnight oil finalizing the patent claims in daily and weekly fillings for months now, and sending relpies to replies back and forth at a break neck pace, to get one of Fountains few world wide patents issued!!! Most of his patents were USA only. This one is international.
That is huge, and very expensive!!!! Like $100,000 to $200,000 kind of expensive!!!!
Could it be they want the patent issued, finalized, licensed to MILV/NDT Pharmaceuticals, Inc, as part of the final steps of the fillings, and contracts, before they turn the lights on and open the grnd opening doors?
I would!!!
The patent is the one he has held in his name, filled for 4 weeks before he let the earlier CCA, LLC patent application die.
He never sold it or licensed it to NuVessl, and NuVessl is not a drug Biotech, NDT Pharmaceuticals is/willl be!!! It's into alcohol containing Ice cream and so on, and skin creams... Not brain trauma drug repair pharmaceuticals.
So we have last minute patent timing delays, auditor delays, COVID19 delays,
I am happy to have the chance to load more MILV bargains from weak hands for a month or so before I retire on $1/shares later this year.
We do know the Judge approved letting the custodian exit and hand over the firm.
I am watching the patent work closely online. If I see a filling of a patent issuing approval by the patent office and an assignment of the patent filling to NDT Pharmaceuticals, Inc, before the Nevada SOS Updates and see buys at .02/share on MILV before SEC fillings, you know I found the holy grail on MILV.
Hedge funds do not watch SEC fillings. The use AI and satellite data to calculate sales based on car traffic at Walmart.
I use my Kung Fu edge at the US patent office, and in research journal articles to see into the future.
SEC is the last place to look for inbound news. The MILV rally started in state court, not in SEC or OTC Fillings. Not on a company web site!!!!
Smart money watches the courts for their clues not the SEC fillings.
I hope that helps????
Lastly, since the company is currently not SEC reporting, they can tweet, pump, post, PR stuff to rally the stock.
WE just must have the strength of conviction to let the Universe unfold MILV as it should.
If the did a PR, or Tweet or other BS crap I would be worried!!!!!
I have no stomach for scams, and If I ever smell a scam I will be the first to say it right here.
I am long MILV and still adding as I can.
